Patents by Inventor Barbara P. Wallner
Barbara P. Wallner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210161902Abstract: Provided herein are methods of using certain Hsp90 inhibitors in treating subjects who have experienced or are experiencing a traumatic brain injury, including lessening the short term impact of such TBI and/or reducing the risk of developing and/or the severity of long term after effects of such TBI.Type: ApplicationFiled: June 22, 2018Publication date: June 3, 2021Applicant: Samus Therapeutics, Inc.Inventor: Barbara P. Wallner
-
Patent number: 8796329Abstract: Organic arsenical compounds are useful to inhibit angiogenesis in a variety of disease conditions.Type: GrantFiled: September 28, 2007Date of Patent: August 5, 2014Assignee: Ziopharm Oncology, Inc.Inventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20140193519Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: August 2, 2013Publication date: July 10, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara P. Wallner, Brian Eric Schwartz, Philip B. Komarnitsky, Gerald Bacher, Bernhard Kutscher, Gerhard Raab
-
Patent number: 8604007Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.Type: GrantFiled: April 4, 2008Date of Patent: December 10, 2013Assignee: Ziopharm Oncology, Inc.Inventors: John C. Amedio, Jr., Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20120295861Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent.Type: ApplicationFiled: July 26, 2012Publication date: November 22, 2012Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Barbara P. WALLNER, Philip B. KOMARNITSKY
-
Patent number: 8252773Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.Type: GrantFiled: October 31, 2008Date of Patent: August 28, 2012Assignee: Ziopharm Oncology, Inc.Inventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20100311689Abstract: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.Type: ApplicationFiled: October 31, 2008Publication date: December 9, 2010Applicant: ZIOPHARM Oncology, IncInventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20080255056Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.Type: ApplicationFiled: April 4, 2008Publication date: October 16, 2008Applicant: ZIOPHARM Oncology, Inc.Inventors: John C. Amedio, Barbara P. Wallner, Philip B. Komarnitsky
-
Publication number: 20080241274Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: November 27, 2007Publication date: October 2, 2008Applicant: ZIOPHARM Oncology, Inc.Inventors: Barbara P. Wallner, Brian Eric Schwartz, Philip B. Komarnitsky, Gerald Bacher, Bernhard Kutscher, Gerhard Raab
-
Publication number: 20080221068Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: ApplicationFiled: October 15, 2007Publication date: September 11, 2008Applicant: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Publication number: 20080139629Abstract: Disclosed are methods for the inhibition of angiogenesis comprising administering an organic arsenical compound.Type: ApplicationFiled: September 28, 2007Publication date: June 12, 2008Applicant: ZIOPHARM Oncology, Inc.Inventors: Barbara P. Wallner, Philip B. Komarnitsky
-
Patent number: 7323171Abstract: Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.Type: GrantFiled: February 13, 2004Date of Patent: January 29, 2008Assignees: Astellas US LLC, The Regents of the University of MichiganInventors: Barbara P. Wallner, Kevin D. Cooper
-
Patent number: 7282484Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: GrantFiled: June 28, 2006Date of Patent: October 16, 2007Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Patent number: 7276371Abstract: Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.Type: GrantFiled: December 1, 2003Date of Patent: October 2, 2007Assignee: Point Therapeutics, Inc.Inventors: William Bachovchin, Barbara P. Wallner
-
Patent number: 7265118Abstract: A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.Type: GrantFiled: July 27, 2005Date of Patent: September 4, 2007Assignee: Point Therapeutics, Inc.Inventor: Barbara P. Wallner
-
Patent number: 7259138Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: GrantFiled: May 17, 2005Date of Patent: August 21, 2007Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn T. Miller
-
Patent number: 7067489Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.Type: GrantFiled: June 28, 2004Date of Patent: June 27, 2006Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams
-
Patent number: 6979697Abstract: A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.Type: GrantFiled: August 13, 1999Date of Patent: December 27, 2005Assignee: Point Therapeutics, Inc.Inventor: Barbara P. Wallner
-
Patent number: 6890904Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.Type: GrantFiled: May 25, 2000Date of Patent: May 10, 2005Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Glenn Miller
-
Patent number: 6770628Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I: wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.Type: GrantFiled: June 11, 2001Date of Patent: August 3, 2004Assignee: Point Therapeutics, Inc.Inventors: Barbara P. Wallner, Barry Jones, Glenn T. Miller, Sharlene Adams